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1. Introduction
Pregabalin, also known by a brand name of Lyr-
ica, is a prescription only gamma-aminobutyric acid 
(GABA) analogue and licensed in different jurisdic-
tions for a broad and diverse range of medical con-
ditions e.g. neuropathic pain, fibromyalgia, general-
ised anxiety and epilepsy [27]. Pregabalin was made 
a controlled drug in 2005 in the United States [27] 
and in 2017 in the United Kingdom [43] due to rec-
ognition of its abuse liability. A central nervous sys-
tem depressant, pregabalin was first reported to the 
European Monitoring Centre for Drugs and Drug Ad-
diction (EMCDDA) Early Warning System in 2009 
[11]. Since then, European prescribing rates have in-
creased, and with increasing concerns around misuse, 
dependence and pregabalin related overdose deaths 
in certain countries (Germany, Finland, Sweden and 
the United Kingdom) [27]. Pregabalin has attracted 
attention in Ireland where our study took place, with 
a marked increase in its association with overdose 
fatalities − from 14 to 65 in Ireland between 2013 
and 2016 [27, 32, 33]. Contributory to such over-
doses is the consumption of much higher doses than 
typically prescribed in order to produce psychoactive 
effects such as euphoria, relaxation and disassocia-
tion [2, 27, 37]. Notably, pregabalin has been shown 
to reduce opiate withdrawal symptomatology and to 
enhance the psychoactive effects of opiates [32]. In 
this regard, individuals with opiate use and those in 
opioid agonist treatment (OAT) are an identified at 
risk group for problematic pregabalin use [29, 32, 
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36]. Recently, an Australian study of toxicology da-
tabases [4], a US register based study [1] and a UK 
analysis of drug screening results [26] have contrib-
uted evidence that polyuse of opiates and pregabalin 
carries an increased risk of fatal overdose. As such, 
research focusing on pregabalin use in individuals in 
OAT is highly relevant. Both opiates and pregabalin 
stimulate central nervous system depression, causing 
sedation, respiratory depression and death [3]. Pre-
gabalin is misused at supra-therapeutic doses with 
bioavailability increased when combined [3].
Prevalence of pregabalin misuse among OAT 
patient’s ranges between 3% to 68%, and with higher 
prevalence of misuse reported among psychiatric pa-
tients and prison inmates. People who use pregaba-
lin experience tolerance and subsequent withdrawal 
symptoms on cessation [3]. Dependence mechanisms 
are not yet well understood. Published empirical re-
search on pregabalin use in Ireland is limited to two 
studies: one which analysed drug screening results of 
individuals in the addiction services [29] and a single 
case study focusing on reported libido enhancing ef-
fects [30]. Two editorials highlight concerns related 
to increasing pregabalin misuse in the Irish context 
[5, 27] which mirror those of international authors. 
Currently, little is known about patterns of pregabalin 
use in individuals who access OAT including motiva-
tors for use, sourcing routes and side effect profiles. 
A need for continued research in this area has been 
highlighted by Irish researchers [5, 27, 29, 30]. This 
paper reports on the first study in Ireland to investi-
gate the experiences of individuals who access OAT 
with pregabalin use. 
Aim: This study aims to add to the existing evi-
dence base and to further national discussion on how 
to improve our healthcare and policy response to this 
emergent trend and associated risks.
2. Methods
Ethical approval for the study was granted by the 
Liverpool John Moore’s University Research Ethics 
Committee (UREC), United Kingdom (19/PHI/005). 
A qualitative descriptive study was conducted using 
semi-structured interviews (SSIs) with 15 individu-
als accessing OAT in an area of Dublin. This service 
provides OAT as well as other essential harm reduc-
tion services. A semi structured interview guide was 
developed based on two studies conducted by author 
two [2, 3] on diverted pregabalin use and included 
topics such as motivators for use, polypharmacy pat-
terns, side effect profiles, views and perceptions of 
risk and sourcing routes. Participants were recruited 
through recruitment posters and via a gatekeeper at 
the service during January and February 2019. The 
gatekeeper signed a confidentiality agreement with 
the research team in protection of the identity of the 
participants. Eligibility criteria included that the indi-
vidual was either currently or previously on an opioid 
agonist programme and had either current or recent 
pregabalin use. Exclusion criteria referred to those 
who had no pregabalin use and to individuals who, 
due to intoxication or other circumstances, a service 
gatekeeper determined as having compromised ca-
pacity to consent to the research. 
2.1. Data collection
One member of the research team interviewed 
participants in a private room at the service between 
March and June 2019. Each interview took approxi-
mately 45 - 60 minutes. All participants were read a 
statement of consent which outlined all relevant in-
formation pertaining to the study. Participants gave 
verbal consent to participation in the study. All par-
ticipants agreed to be audio recorded. They were 
assured all personal identifiers would be removed 
in order to ensure confidentiality. Participants were 
informed of the availability of a counselling service 
for any individual should they become distressed or 
affected by the topics discussed at interview, and of 
their right to revoke their consent to interview at any 
time without recourse.
2.2. Data analysis
Audio recordings were transcribed verbatim. 
Data was analysed using applied thematic analysis 
[16]. Transcripts were read by both research team 
members. Based on the literature review conducted 
and the interview guide used, a preliminary thematic 
structure was developed as the researchers familiar-
ized themselves with the data and sorted it under over-
arching emergent themes. Coding was aided by use of 
NVivo12 software. This initial thematic structure was 
advanced as each researcher coded an individual tran-
script and indicative themes emerged from the data. 
To establish intercode reliability, discrepancies in 
coding were discussed between both team members 
and further codebooks (N=2) developed. All tran-
scripts were revisited with the final codebook and the 
data interrogated using the final thematic framework. 
In the ethos of participatory research, once data was 
coded, author one visited the service during October 
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2019 and conducted a “participant check” [24]. Re-
search findings were presented to participants one to 
one and confidentially, and feedback was sought to 
ensure that their authentic voices were accurately rep-
resented in the author’s interpretations.
3. Results
15 individuals partook in the interviews, with 
ages ranging from 25 to 45 years (nine male/six fe-
male). Twelve of these were currently accessing OAT 
and three had transitioned from treatment. Lyrica was 
the common drug used when referring to pregabalin.
3.1. Lyrica use patterns, motivators for use and side 
effect profile
Half of all participants reported being initially 
prescribed Lyrica legitimately for, mainly, pain re-
lated conditions. Problematic use and increases in 
amounts developed rapidly for OAT participants in 
this category, who described motivators for using 
supra-therapeutic doses as enhanced sociability; re-
duced anxiety; increased confidence, and relief from 
emotional distress. The remaining half of participants 
reported their first use of Lyrica as diverted medica-
tion occurring through peer networks. For many par-
ticipants Lyrica use was embedded in a polydrug use 
culture of “tablet taking”, where diverted prescrip-
tion medication such as benzodiazepines, z-hypnotics 
and painkillers were used, either daily, in isolation or 
socially. For some, a longstanding relationship with 
“tablets”, such as diazepam, had led to the initiation 
of Lyrica use. The self-regulation of negative emo-
tions through Lyrica use was noted in OAT partici-
pants. A substantial evidence based exists on the use 
of illicit substances to regulate emotions and to cope 
with past trauma and life stressors [7, 20, 21, 42, 44]. 
In the following illustrative quotes, Lyrica was de-
scribed as a coping strategy: 
“They say a high, but tablets don’t give you a 
high. It’s just a relaxed, fuck everything kind of feel-
ing. Forget about all that. You don’t have to deal with 
that until tomorrow…or next week…whatever. That’s 
why I do it cos most things, I don’t want to deal with. 
I can’t even handle that shit. Do you know what I 
mean?” (Participant 2, female).
“They numb the shit, the pain that you…the loss. 
They knocked all that out.” (Participant 4, female)
“It was prescribed to me for pain. It was given 
to me then. I didn’t know about the buzz out of them. 
I didn’t even read the leaflets. It was just given to me 
for pain relief. It stopped the pain in my knees. But 
then I started overtaking them and I was getting that 
false confidence. That’s what I take them for...that 
false confidence…I’m able to be out there. Without 
them, I’m in my shell….I’m taking them to be a false 
me. I have issues that I haven’t dealt with.” (Partici-
pant 9, male)
Indications of self-regulation of negative emo-
tions with increasingly larger doses are also consist-
ent with the findings of a single case report of a male 
diagnosed with pregabalin use disorder [35].
As documented previously [5], the physiologi-
cal effects of Lyrica were described as comparable 
to alcohol intoxication: “when you’re in that Lyrica 
bubble, it’s like you’re buckled drunk” (participant 
1, male). For that reason, few participants reported 
drinking alcohol when consuming Lyrica. The con-
sumption of large dosages already noted in the lit-
erature [13] was also seen in this study, and ranged 
from 800 mg daily (prescribed dose) to an incident 
of ingestion of 6000 mg in one episode. Many par-
ticipants reported dosages in excess of 1000 mg daily. 
One participant described his experiences of overdos-
ing twice on Lyrica:
“I overdosed twice. The first time I OD’d they 
gave me charcoal……the second time, I went blue and 
I ended up getting pneumonia and that. That snapped 
me out of it, and I said I’m not taking them like that… 
so I went up to the doctors. When my mate saw me in 
the hospital when I died...he said, “I’m never giving 
you them again”. (Participant 7, male).
Routes of administration were largely oral, swal-
lowing or chewing, with insufflation also reported by 
some. While some participants reported knowledge of 
injecting use by peers, all stated injecting was some-
thing they would not return to, due to its association 
with past problematic heroin use. Delayed effects, 
prompting re-dosing, were reported, perhaps due to 
procurement of a type of controlled release Lyrica 
called GLA5PR GLARS-NF1 [40]. Undesirable side 
effects described included loss of consciousness; 
vomiting; loss of control and out of character behav-
iours such as shoplifting, and aggression attributed to 
feelings of invincibility: 
“It’s got me into a lot of trouble. I’ve had a few 
charge sheets. From…when I take them, I forget, like 
that I feel like I’m invisible, I do more stuff. I’ve been 
fighting…They’re mad they send you off your head” 
(Participant 12, female)
“When you’re on the tablets like, you think 
you’re invincible, that no one can see you…last time I 
was on Lyrica I got a charge sheet…I thought people 
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were winking at me and letting me take things (shop-
lift) …and then I get caught” (Participant 2, female). 
3.2. Sourcing
A combination of legitimate and illegitimate 
sourcing routes and displacement between these 
routes were described. In participants who initiated 
their Lyrica use through a doctor’s prescription, many 
transitioned to street sourcing to supplement their 
prescribed use. Conversely, some participants who 
initiated with “street” use transitioned to prescribed 
use. As seen in a number of population groups with 
problematic use of prescribed benzodiazepines and 
opioids [15, 39], some participants reported drug 
seeking behaviours such as exaggeration of symp-
toms; visiting multiple doctors or “doctor shopping” 
(seen also in studies of pregabalin use [4, 9]). Diver-
sion of the prescriptions of family and friends and 
attempts at prescription forgery in order to obtain 
Lyrica were also described. While there were some 
reports of careful assessment by doctors, where par-
ticipants found it difficult to obtain Lyrica, there were 
also a number of concerning reports of obtaining 
Lyrica from doctors and pharmacists illegitimately, a 
rogue practice documented, for example, in the case 
of prescription opioids in the US [39]. Cash sales of 
Lyrica have also previously been documented in a mi-
nority of pharmacists in Jordan, Egypt [2]. Inappro-
priate prescribing by general practitioners was also 
described by participants:
“I know of doctors who if you slip them fifty 
quid, they’ll give you Lyrica…meet you in the car-
park…whatever.” (Participant 1, male)
“I’m a regular for going back to the doctor early 
and he used to be grand....I would be going’ back eve-
ry ten days instead of every two weeks and he would 
always give it.” (Participant 4, female)
An additional sourcing route described by one 
participant was through social media site Face Book, 
where an unknown seller would initiate contact 
through a friend request and accept payment through 
Western Union. The selling of controlled substances 
through social media has been documented previ-
ously [8, 41].
3.3. Dependence and withdrawal 
Consistent with previous reports [4, 35, 38, 46] 
,indications of dependence symptomatology (e.g. tol-
erance and withdrawal) were illustrated in some par-
ticipant’s narratives:
“They’re ruling my life like. They are ruling my 
life. I won’t go anywhere without…” (Participant 4, 
female)
Withdrawals from Lyrica were described by a 
number of participants, many with prior experience 
of withdrawing from opiates, as remarkably severe. 
Recently, Schifano and Chiappini [37] highlighted 
that a research lacuna exists in documenting the ex-
periences of individuals after detoxification who had 
voluntarily sought help for dependent use of prega-
balin. One participant in our study, no longer using 
Lyrica, describes how he self-detoxified at home:
“It wasn’t a slight... withdrawal. It was horrible. 
I couldn’t hold anything in my body. If I wasn’t cry-
ing, I was throwing up. I had no energy at all. I was 
basically crying the whole way through. It was hor-
rific. Going from the bathroom to the bed. I’d never 
felt like that before. When I was going through with-
drawals from methadone, I was able to eat. I was still 
able to do all that. (With Lyrica) I was like that for 
about nine days... the effects on my head lasted way 
longer… at least a month. I was paranoid, I felt I had 
no worth.” (Participant 6, male)
Another participant sought help with dependent 
use of “street” sourced Lyrica through a supervised 
medical detox:
“Then I got them prescribed from my doctor…I 
asked him to detox me. He didn’t want to, but I said 
if you don’t give them to me, I’m gonna die off them. 
I needed them I was addicted to them. I was on three 
a day for a couple a month, then two a day for a 
month and now one a day. I get them takeaways twice 
a week. I give him to my ma; she leaves one a day 
on the locker for me with my methadone. I’m finished 
next week.” (Participant 7, male)
A single case study published in 2018 [17] de-
tails a first episode of psychosis attributed to pregaba-
lin withdrawals where the patient suffered paranoia, 
hallucinations, self-harm and suicide. Similar psychi-
atric symptoms were described by participants in this 
study when discussing their withdrawals from Lyrica:
“Cold turkey. Don’t ever try cold turkey. It’s like 
dying sick from other tablets...the only difference re-
ally is the psychosis part of it...you don’t fit in your 
skin…you’re on a weird type of buzz like. You’re agi-
tated, you’re overstressed, your fear, it’s ten times 
worse. You won’t talk to people. Lyrica is different 
that way, the psychosis is worse.” (Participant 8, male)
“The withdrawals…and then it’s kind of like, a 
bit of psychosis in the head like...you’d find yourself 
sitting there and you’re actually having a conversa-
tion with yourself in your head… I just lock myself in, 
- 9 -
R. Brennan & M.C. Van Hout: "Bursting the lyrica bubble”: Experiences of pregabalin use in individuals accessing opioid agonist treatment in 
Dublin, Ireland. 
In line with this theory, two participants suggested 
that due to the strong effects of Lyrica, many people 
without problematic drug use would not be as likely 
to use them:
“I think mostly its people in addiction. People 
who just take (drugs) here and there…I can’t see them 
liking them. They’re so strong... unless I had another 
habit, I wouldn’t like the feeling of it. Whereas be-
cause I already had a tablet habit, I was able for it.” 
(Participant 6, male)
“You’d have to take heroin or foy (methadone) 
or stuff like that. To be able to handle it.” (Participant 
11, male)
3.5. Perceived harms and harm reduction strategies
Risk perceptions were centred on the fear of 
overdose, as seen previous research [26] and which 
was largely due to local and communal knowledge of 
fatalities or negative personal experiences: 
“My best mate died of Lyrica only three or four 
years ago …she had Lyrica, drink, gear (heroin) ...a 
load of different things. When I go to bed, I think of 
that…. I think all drugs are the same, but I just hear 
of more deaths from Lyrica. I think that people are 
mixing them….and like me I just kept swallowing and 
swallowing and swallowing…. my heart was thump-
ing, I had to open the window and breathe properly 
and calm down.” (Participant 2, female) 
Indigenous harm reduction measures were seen 
in the data where participants described the avoidance 
of counterfeit Lyrica through only purchasing those 
that were encased in foil sheets (as opposed to loose 
tablets); asking questions about whether the Lyrica 
came from a chemist and reducing their own use: 
“I had a bad experience. I will not buy street 
tablets. I took fake Trannex and collapsed and was 
in (name of hospital) for three weeks. If I’m buy-
ing tablets, I have to see them in the wrapper. And 
the dates...I go that far I check the dates. I know the 
cards…I know the shape of the card. I’ll pop it out 
of the thing… and I’ll know how far the colours go.” 
(Participant 9, male)
4. Discussion
We present here the findings from the first quali-
tative study in Ireland to explore pregabalin use from 
the perspectives of Irish OAT patients, which are 
identified in the literature as a key user group. Analy-
sis of the current trend for high dose Lyrica use in this 
population and potential responses may be conceptu-
I might as well be in a prison cell. I can feel the walls 
closing in… I have a big fear of just dropping them. 
I did try drop them…and I nearly went off my head. 
I had to go back to my doctor and lie to him straight 
away. I got ten days out of it. I was emotional…sui-
cidal. I couldn’t even talk.” (Participant 9, male)
3.4. Polydrug use repertoires and Lyrica intersection 
with opioids
As documented in previous studies [6, 12] 
Lyrica use was situated within habituated polydrug 
use practices for many participants, which included 
prescribed and “street” use of methadone, benzodi-
azepines, z-hypnotics and also use of stimulants such 
as crack cocaine and “snow blow”, a synthetic cathi-
none. Use of Lyrica, a CNS depressant, to “come 
down” from stimulants was reported by some partici-
pants, in addition to concurrent use to enhance the ef-
fects of other substances, as illustrated by this quote 
from a participant speaking about using crack cocaine 
and Lyrica together:
“It’s like a hybrid. It’s pleasant…it calms…but 
you’ve still got a little bit of the crack going on in 
your brain as well… and then you’ve got the Lyrica 
coming in to counter it, it’s like balancing the scales” 
(Participant 1, male)
To date, researchers have not been able to pin-
point exactly why pregabalin misuse is popular 
among individuals with opioid use [37]. The data 
from this study agreed with previously documented 
findings [12, 26] on the ameliorating effects of Lyrica 
on opiate withdrawal syndrome: 
“Better than Zimmovaines or D10s (diazepam), 
Lyrica will hold you until the next morning” (Partici-
pant 10, female). 
Moreover, one participant reported using Lyrica 
legitimately to aid with his methadone detox. How-
ever, more nuanced comparisons were made between 
opiate use and Lyrica use by some participants who 
recalled a similar relationship to heroin at one point 
in their lives: 
“You know what it reminds me of? Using gear 
back in the 90s…scamming money...do you know what 
I mean... If you don’t take them like, first thing my 
leg starts going and that reminds me of gear, straight 
away. Then the back, and then the skin. It’s like being 
sick off gear. It’s taking over you. It’s a hundred per-
cent like it.” (Participant 9, male)
One study suggested that high tolerance to sub-
stances after long-term opioid use may cause an in-
clination to use newer drugs such as pregabalin [14]. 
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depression, hallucinations and suicidal ideation. In-
dividuals in OAT are particularly vulnerable to self-
isolation and feelings of depression [28]. Pregabalin 
withdrawal syndrome should be considered as an ad-
ditional risk factor for acute psychiatric symptoms 
including suicidal thoughts by medical professionals 
and service providers. Awareness amongst service 
providers around the potential for “home detoxifica-
tion” where individuals may become vulnerable, iso-
lated and unwell is warranted, so that those who wish 
to stop their pregabalin use can be supported to do so 
in a safe and medically supervised way if necessary. 
Polydrug use is an area of public health concern 
and has also been described as “the norm” in drug us-
ing populations [19]. For most participants, as seen in 
previous research [6, 12] pregabalin was embedded in 
polydrug use repertoires. Again, polydrug use is as-
sociated with trauma [18] and individuals may access 
a range of substances to regulate their emotions. In 
addition to the recommendations already made with 
regard to trauma informed care, an efficient health-
care response to polydrug use should be focused on 
the delivery of pragmatic harm reduction information 
around potentially lethal combinations and reduction 
of amounts. One finding of our study was that partici-
pants may be unwarily accessing a type of controlled 
release pregabalin which heightens re-dose potential. 
Awareness needs to be raised around re-dosing risks 
specific to this finding. Participants in our study ex-
alised using a socio ecological model (see Figure 1) 
which considers individual, community and systemic 
factors creating a risk environment unique to time and 
space [34].
Causal factors in the significantly higher rates of 
problematic pregabalin use amongst the OAT popula-
tion have been documented in the literature, e.g. to 
relieve opioid withdrawal syndromes or enhance the 
effects of opioids [12, 26] and due to its potent intoxi-
cating effects [14]. The data from this study agreed 
with such previous findings, and also draws a com-
parison between the descriptions of pregabalin use 
by participants and the hypothesis of self-medication 
theory [20, 21]. Self-medication theory posits that 
problematic substance use is grounded in the relief 
of “distressing psychological symptoms” [7]. Many 
participants described using Lyrica to “cope” with 
feelings of anxiety or loss. There is a strong associa-
tion between OAT patients and trauma [28, 45] which 
may include a multiplicity of adverse childhood 
events (ACEs) [31]. In this regard, trauma informed 
interventions, practices and services [22] would be 
a valuable approach in responding to the needs of 
OAT patients using pregabalin drugs, such as Lyrica. 
Trauma informed practices include training for staff 
and adaptation of the clinical environment to support 
emotional regulation in service users. Our study con-
tained reports of psychiatric symptoms in individuals 
withdrawing from pregabalin use, including anxiety, 
Individual Risk Factors 
- self regulation of negative 
affect
-management of opioid 
withdrawal syndrome
-chronic pain 
-lack of harm reduction 
resources 
Community/ Organisational 
Risk Factors 
- need for vigilant GP
prescribing and pharmacy 
dispensing
-insufficient risk assessments 
and patient reviews in 
vulnerable populations
-insufficient consideration of 
alternatives for pain relief
Systemic Risk Factors
- need for trauma informed 
services 
- Lyrica rescheduling
considerations
- need for enhanced public 
health awareness campaigns 
re: overdose and polydrug use 
Figure 1. The risk environment for problematic Lyrica use in the opioid agonist population in an area of Dublin, 
Ireland 
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dangerous consequences for people who take them. 
Although many participants were resourceful in de-
veloping strategies to protect themselves from the 
procurement of counterfeit Lyrica, harm reduction 
programmes should contain safeguards in recognis-
ing illicitly manufactured and counterfeit drugs. 
The main limitation of this study is that its small 
sample size and localized nature does not allow for 
generalisation. The data is also self-reported and may 
be subject to recall bias, particularly in recollections 
of overdose. However the reliability of self-report 
measures in people who use drugs has been validated 
previously [23]. Due to the nature of polydrug use, 
causal inferences cannot be made about the effects 
of Lyrica. However, we interviewed a range of indi-
viduals of both genders, with authentic accounts of 
polydrug use with Lyrica and other substances, which 
contribute valuable insight into their experiences. We 
are unaware of any other Irish study prior to ours to 
document qualitative evidence of the experiences of 
pregabalin in the in-treatment population. 
5. Conclusions
We found that pregabalin (Lyrica) use in indi-
viduals accessing OAT in an area of Dublin, Ireland 
was associated with self-regulation of negative affect; 
a combination of legitimate and illegitimate sourc-
ing routes and severe withdrawal syndrome including 
psychiatric symptoms. Increased general practitioner 
and pharmacist vigilance in relation to prescribing 
and dispensing of Lyrica and enhanced risk assess-
ment protocols when responding to presentations for 
pain relief are needed. Trauma informed practices 
in services and increased delivery of tailored drug 
specific and polydrug harm reduction information 
to prevent overdose in this high-risk group is recom-
mended.
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